|
GLUD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.34590030629067E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.39520000003368E-07 |
| Normal-vs-Stage2 |
1.55309998195463E-09 |
| Normal-vs-Stage3 |
3.49009998679151E-09 |
| Normal-vs-Stage4 |
1.1497999996557E-08 |
| Stage1-vs-Stage2 |
1.307730E-02 |
| Stage1-vs-Stage3 |
1.258580E-01 |
| Stage1-vs-Stage4 |
5.223700E-02 |
| Stage2-vs-Stage3 |
3.775200E-01 |
| Stage2-vs-Stage4 |
6.984400E-01 |
| Stage3-vs-Stage4 |
6.248600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.27429997057271E-09 |
| Normal-vs-AfricanAmerican |
1.836450E-04 |
| Normal-vs-Asian |
1.920880E-03 |
| Caucasian-vs-AfricanAmerican |
9.356400E-01 |
| Caucasian-vs-Asian |
4.914000E-01 |
| AfricanAmerican-vs-Asian |
5.546400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.20530000424779E-08 |
| Normal-vs-Female |
1.99170002712634E-09 |
| Male-vs-Female |
6.742400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.611900E-04 |
| Normal-vs-Age(41-60Yrs) |
5.55040458039002E-11 |
| Normal-vs-Age(61-80Yrs) |
1.07470032872925E-10 |
| Normal-vs-Age(81-100Yrs) |
2.835800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.058300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.834300E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.524000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.799600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.200400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.754000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.774400E-01 |
| Classical-VS-Follicular |
9.94099999984677E-07 |
| Classical-VS-Other |
5.693400E-01 |
| Classical-VS-Normal |
5.89799999950458E-07 |
| Tall-VS-Follicular |
9.739500E-03 |
| Tall-VS-Other |
6.636000E-01 |
| Tall-VS-Normal |
2.785400E-04 |
| Follicular-VS-Other |
3.491000E-01 |
| Follicular-VS-Normal |
3.90476539990914E-12 |
| Other-VS-Normal |
1.280010E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.70574665503409E-12 |
| Normal-vs-N1 |
2.61639999998842E-07 |
| N0-vs-N1 |
9.916200E-01 |
|
|
